Latest Headlines

Online Exclusive

Senator Pushes Pfizer to Permanently Roll Back Prices

U.S. Senator Tammy Baldwin (D-WI) has written to Pfizer CEO Ian Read asking the company to “permanently roll back” the prices for its prescription...

CMS Proposes Reimbursing Doctors for Telehealth

The Centers for Medicare and Medicaid Services (CMS) has proposed the first major overhaul of Medicare billing practices since 1995. Under the new rules,...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Pulling Back the Curtain: Allison Rosenthal, DO

Hear more from our interview with Dr. Rosenthal, where she talks about the best career advice she's ever received and the best (and worst) parts of...
video

Expanding Acalabrutinib to Waldenström Macroglobulinemia

Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
video

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...
video

Enhancing Ibrutinib With Rituximab in Waldenström Macroglobulinemia

Combining ibrutinib with rituximab led to longer progression-free survival, compared with ibrutinib alone, in patients with Waldenström macroglobulinemia. Meletios Dimopoulos, MD, shares results from...

On Location

Axicabtagene Ciloleucel Moves to Acute Lymphocytic Leukemia

Axicabtagene ciloleucel, which in October 2017 became the first chimeric antigen receptor (CAR) T-cell therapy...

Moxetumomab Pasudotox: An Alternative to Chemotherapy in Hairy Cell Leukemia

In a pivotal phase III clinical trial of moxetumomab pasudotox in patients with relapsed/refractory hairy...

Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment

Patients with previously untreated chronic myeloid leukemia (CML) who received bosutinib were more likely than...

bb2121: Is CAR T-Cell Therapy Moving to Myeloma?

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of acute lymphocytic leukemia and...

Acalabrutinib Induces Durable Response in Patients With Waldenström Macroglobulinemia

In a phase II study of patients with Waldenström macroglobulinemia (WM), treatment with the highly...

Evaluating FT-2102 in IDH1-Mutated AML or MDS

According to interim data from a first-in-human phase I trial, treatment with FT-2102, a selective...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
5,887SubscribersSubscribe

EURO-SKI: Can Patients With CML Stop Tyrosine Kinase Inhibitors?

Treatment with tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, and dasatinib, has increased the rates of survival and response over previously available therapies for...

Presence of Minimal Residual Disease Predicts Relapse and Survival in AML

For patients with acute myeloid leukemia (AML), the detection of molecular minimal residual disease (MRD) in patients achieving morphologic complete remission (CR) was associated...

Complete Mutation Clearance Predicts Longer Survival and Lower Relapse Risk in AML

Somatic mutation clearance (MC) at complete remission (CR) of acute myeloid leukemia (AML) was associated with improved survival and reduced risk of relapse, according...

Psychiatric Comorbidities of Myeloma Lead to High Health-Care Costs

Many patients with multiple myeloma (MM) have a high risk for developing psychiatric comorbidities and, according to a study published in Blood Advances, managing...

FDA Opens Communication Lines Between Drug Makers and Insurers

The U.S. Food and Drug Administration (FDA) has issued final guidance documents outlining the types of information that drug companies may share with insurers,...